- Home
- PPBT vs BNZI Comparison
PPBT vs BNZI Comparison
Compare PPBT & BNZI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- BNZI
- Stock Information
- Founded
- PPBT 2010
- BNZI 2016
- Country
- PPBT Israel
- BNZI United States
- Employees
- PPBT N/A
- BNZI N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- BNZI
- Sector
- PPBT Health Care
- BNZI
- Exchange
- PPBT Nasdaq
- BNZI Nasdaq
- Market Cap
- PPBT 6.2M
- BNZI 11.5M
- IPO Year
- PPBT N/A
- BNZI N/A
- Fundamental
- Price
- PPBT $2.53
- BNZI $3.87
- Analyst Decision
- PPBT Strong Buy
- BNZI Strong Buy
- Analyst Count
- PPBT 1
- BNZI 1
- Target Price
- PPBT $33.00
- BNZI $24.00
- AVG Volume (30 Days)
- PPBT 18.2K
- BNZI 477.6K
- Earning Date
- PPBT 08-15-2025
- BNZI 08-13-2025
- Dividend Yield
- PPBT N/A
- BNZI N/A
- EPS Growth
- PPBT N/A
- BNZI N/A
- EPS
- PPBT N/A
- BNZI N/A
- Revenue
- PPBT N/A
- BNZI $6,827,490.00
- Revenue This Year
- PPBT N/A
- BNZI $337.60
- Revenue Next Year
- PPBT N/A
- BNZI $91.81
- P/E Ratio
- PPBT N/A
- BNZI N/A
- Revenue Growth
- PPBT N/A
- BNZI 52.95
- 52 Week Low
- PPBT $2.00
- BNZI $3.80
- 52 Week High
- PPBT $13.95
- BNZI $112.00
- Technical
- Relative Strength Index (RSI)
- PPBT 56.04
- BNZI 24.22
- Support Level
- PPBT $2.35
- BNZI $3.93
- Resistance Level
- PPBT $2.58
- BNZI $6.90
- Average True Range (ATR)
- PPBT 0.12
- BNZI 0.63
- MACD
- PPBT 0.02
- BNZI -0.12
- Stochastic Oscillator
- PPBT 84.38
- BNZI 2.12
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.